NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Syros Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.60 -0.04 (-0.86 %) (As of 12/6/2019 04:00 PM ET) Add Compare Today's Range$4.55Now: $4.60▼$4.7450-Day Range$4.60MA: $5.23▼$6.8452-Week Range$4.53Now: $4.60▼$11.93Volume190,081 shsAverage Volume199,908 shsMarket Capitalization$195.23 millionP/E RatioN/ADividend YieldN/ABeta1.47 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYRS Previous Symbol CUSIPN/A CIK1556263 Webhttp://www.syros.com/ Phone617-744-1340Debt Debt-to-Equity Ratio0.20 Current Ratio4.92 Quick Ratio4.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.05 million Price / Sales95.23 Cash FlowN/A Price / Cash FlowN/A Book Value$2.34 per share Price / Book1.97Profitability EPS (Most Recent Fiscal Year)($1.91) Net Income$-62,280,000.00 Net Margins-3,115.38% Return on Equity-84.49% Return on Assets-60.09%Miscellaneous Employees76 Outstanding Shares42,441,000Market Cap$195.23 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive SYRS News and Ratings via Email Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SYRS Rates by TradingView Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions What is Syros Pharmaceuticals' stock symbol? Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS." How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals Inc (NASDAQ:SYRS) issued its earnings results on Tuesday, November, 12th. The company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.01. The business had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. View Syros Pharmaceuticals' Earnings History. When is Syros Pharmaceuticals' next earnings date? Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals. What price target have analysts set for SYRS? 7 brokers have issued 12-month price targets for Syros Pharmaceuticals' shares. Their forecasts range from $10.00 to $18.00. On average, they expect Syros Pharmaceuticals' stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 215.2% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals. What is the consensus analysts' recommendation for Syros Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals. Has Syros Pharmaceuticals been receiving favorable news coverage? News stories about SYRS stock have trended extremely negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Syros Pharmaceuticals. Are investors shorting Syros Pharmaceuticals? Syros Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 2,590,000 shares, an increase of 8.8% from the October 31st total of 2,380,000 shares. Based on an average daily volume of 234,100 shares, the days-to-cover ratio is currently 11.1 days. Approximately 8.6% of the company's stock are sold short. View Syros Pharmaceuticals' Current Options Chain. Who are some of Syros Pharmaceuticals' key competitors? Some companies that are related to Syros Pharmaceuticals include CannTrust (CNTTF), Eagle Pharmaceuticals (EGRX), TG Therapeutics (TGTX), Aurinia Pharmaceuticals (AUPH), Flexion Therapeutics (FLXN), Akebia Therapeutics (AKBA), Revance Therapeutics (RVNC), Kura Oncology (KURA), ANI Pharmaceuticals (ANIP), Collegium Pharmaceutical (COLL), Homology Medicines (FIXX), Synthorx (THOR), TherapeuticsMD (TXMD), Axovant Sciences (AXON) and Phathom Pharmaceuticals (PHAT). What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Nektar Therapeutics (NKTR), Sangamo Therapeutics (SGMO), ImmunoGen (IMGN), ZIOPHARM Oncology (ZIOP), Zynerba Pharmaceuticals (ZYNE), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD) and Global Blood Therapeutics (GBT). Who are Syros Pharmaceuticals' key executives? Syros Pharmaceuticals' management team includes the folowing people: Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)Dr. David A. Roth, Chief Medical Officer (Age 56)Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Syros Pharmaceuticals' major shareholders? Syros Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (10.92%), Sumitomo Mitsui Trust Holdings Inc. (10.92%), Redmile Group LLC (9.16%), State Street Corp (1.59%), Millennium Management LLC (0.04%) and Barclays PLC (0.04%). Company insiders that own Syros Pharmaceuticals stock include Jeremy P Springhorn, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View Institutional Ownership Trends for Syros Pharmaceuticals. Which institutional investors are selling Syros Pharmaceuticals stock? SYRS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Richard A Young and Venture Fund Vii LP Arch. View Insider Buying and Selling for Syros Pharmaceuticals. Which institutional investors are buying Syros Pharmaceuticals stock? SYRS stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Redmile Group LLC, State Street Corp, Millennium Management LLC, Metropolitan Life Insurance Co NY and Tower Research Capital LLC TRC . Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Syros Pharmaceuticals' stock price today? One share of SYRS stock can currently be purchased for approximately $4.60. How big of a company is Syros Pharmaceuticals? Syros Pharmaceuticals has a market capitalization of $195.23 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals. What is Syros Pharmaceuticals' official website? The official website for Syros Pharmaceuticals is http://www.syros.com/. How can I contact Syros Pharmaceuticals? Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected] MarketBeat Community Rating for Syros Pharmaceuticals (NASDAQ SYRS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 298 (Vote Outperform)Underperform Votes: 265 (Vote Underperform)Total Votes: 563MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/6/2019 by MarketBeat.com StaffFeatured Article: What is a blue-chip stock?